Here’s a roundup of the latest coronavirus-related news.
The coronavirus disease 2019 (COVID-19) vaccination effort is well underway in the US, with over 26 million administered doses and 1.3% of the population fully vaccinated against the virus as of press time. This week, the Biden-Harris administration announced updates on vaccine rollout, and new data was released on therapies and vaccines for severe acute respiratory syndrome (SARS-CoV-2).
Here’s a roundup of the latest coronavirus-related news:
NCPA Supports Biden-Harris COVID-19 National Strategy
The National Community Pharmacists Association (NCPA) has issued a statement to express its approval of the Biden administration’s COVID-19 national strategy and commitment to work with President Biden in executing this strategy, as well as other initiatives moving forward.
Biden Administration Announces Steps to Ramp Up COVID-19 Vaccine Rollout
President Joe Biden announced several measures aimed at ramping up COVID-19 vaccination efforts, including the purchase of 200 million more vaccine doses for the United States.
COVID-19 Vaccine: CDC Updates Guidance on Interchangeability, Dosage Intervals
The CDC’s Advisory Committee on Immunization Practices (ACIP) has updated its interim recommendations for COVID-19 vaccines.
Study: Bamlanivimab-Etesevimab Combo Treatment for High-Risk COVID-19
Eli Lilly and Company announced study results showing significant improvements in hospitalization and death rates among high-risk patients recently infected with COVID-19 with its antibody therapies.
Prior Metformin Use Reduces COVID-19 Mortality Risk in Patients With Diabetes
Results of a recent study suggest that taking metformin prior to COVID-19 diagnosis reduced mortality in individuals with type 2 diabetes.
American Heart Association Report Predicts COVID-19 Effects on Cardiovascular Disease Burden
The American Heart Association’s 2021 Statistical Update reported that heart disease remains the leading cause of death worldwide, and COVID-19 may have an impact on cardiovascular health and mortality rates for years to come.
ACIP Meeting: COVID-19 Vaccine Safety Updates
On Wednesday, an emergency virtual meeting of the CDC’s ACIP provided an update on COVID-19 vaccine safety.
Johnson & Johnson Reports Efficacy Rates of COVID-19 Vaccine Candidate
Johnson & Johnson’s COVID-19 vaccine candidate is 66% effective in preventing moderate-to-severe COVID-19 and met all primary and secondary end points of its phase 3 ENSEMBLE clinical trial, according to a news release published on Friday.
How Does Digital Data Help Improve QOL in Patients With Long COVID and Autoimmune Diseases?May 30th 2023
Quality of life (QOL) for people living with autoimmune diseases benefits from an integrated approach that considers individual immune system sensitivities and patients’ life circumstances, a new study shows.
2 Clarke Drive
Cranbury, NJ 08512